Mustang Bio Inc (MBIO) - Total Liabilities
Based on the latest financial reports, Mustang Bio Inc (MBIO) has total liabilities worth $8.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MBIO financial resilience to evaluate the company's liquid asset resilience ratio.
Mustang Bio Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Mustang Bio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Mustang Bio Inc.
Mustang Bio Inc Competitors by Total Liabilities
The table below lists competitors of Mustang Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WestKam Gold Corp
V:WKG
|
Canada | CA$880.07K |
|
Azitra Inc
NYSE MKT:AZTR
|
USA | $1.22 Million |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
Germany | €554.12 Million |
|
Morarjee Textiles Limited
NSE:MORARJEE
|
India | Rs9.20 Billion |
|
Norcros Plc
LSE:NXR
|
UK | GBX175.00 Million |
|
Linkage Global Inc
NASDAQ:UZX
|
USA | $5.02 Million |
|
Ashtead Technology Holdings PLC
LSE:AT
|
UK | GBX166.19 Million |
|
Marvel Discovery Corp
V:MARV
|
Canada | CA$1.86 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Mustang Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Mustang Bio Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mustang Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mustang Bio Inc (2015–2025)
The table below shows the annual total liabilities of Mustang Bio Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.06 Million | -38.82% |
| 2024-12-31 | $13.18 Million | -25.19% |
| 2023-12-31 | $17.62 Million | -61.82% |
| 2022-12-31 | $46.15 Million | +261.39% |
| 2021-12-31 | $12.77 Million | +11.38% |
| 2020-12-31 | $11.46 Million | -47.39% |
| 2019-12-31 | $21.79 Million | +242.77% |
| 2018-12-31 | $6.36 Million | +73.67% |
| 2017-12-31 | $3.66 Million | +13.59% |
| 2016-12-31 | $3.22 Million | -21.94% |
| 2015-12-31 | $4.13 Million | -- |
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB… Read more